PUMA in head and neck cancer

被引:39
作者
Hoque, MO
Begum, S
Sommer, M
Lee, T
Trink, B
Ratovitski, E
Sidransky, D
机构
[1] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
关键词
PUMA; tumor suppressor gene; HNSCC; p53; mutation;
D O I
10.1016/S0304-3835(03)00344-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic alterations of p53, which monitors DNA damage and operates cellular checkpoints, is a major factor in the development of many types of cancer in human. PUMA, a direct mediator of p53-associated apoptosis, was recently identified. The PUMA gene was mapped to chromosomal arm 19q, a region frequently deleted in head/neck and lung cancers. We analyzed 30 primary tumors (15 head/neck and 15 lung) for loss of heterozygosity (LOH) at 19q using seven widely spaced microsatellite markers. LOH in at least one marker was present in 8 (56%) of the head/neck and 4 (26.6%) of the lung cancer samples. Overall, D19S408 and D19S412, showed the highest rates of allelic loss (23.3 and 16.6%, respectively). We then sequenced the entire coding region of the PUMA gene in all the 30 primary tumors and in 10 head/neck cancer cell lines. No mutations of PUMA were detected in any samples examined, regardless of the mutational status of the p53 gene. Forced expression of wild-type PUMA in JHU-012 and JHU-013 head/neck cancer cell lines significantly inhibited colony formation. Although PUMA suppresses tumor cell growth in head/neck cancer, it does not appear to be a direct target of inactivation in head and neck tumorigenesis. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 39 条
[1]   Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array [J].
Ahrendt, SA ;
Halachmi, S ;
Chow, JT ;
Wu, L ;
Halachmi, N ;
Yang, SC ;
Wehage, S ;
Jen, J ;
Sidransky, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (13) :7382-7387
[2]   FREQUENCY OF HOMOZYGOUS DELETION AT P16/CDKN2 IN PRIMARY HUMAN TUMORS [J].
CAIRNS, P ;
POLASCIK, TJ ;
EBY, Y ;
TOKINO, K ;
CALIFANO, J ;
MERLO, A ;
MAO, L ;
HERATH, J ;
JENKINS, R ;
WESTRA, W ;
RUTTER, JL ;
BUCKLER, A ;
GABRIELSON, E ;
TOCKMAN, M ;
CHO, KR ;
HEDRICK, L ;
BOVA, GS ;
ISAACS, W ;
KOCH, W ;
SCHWAB, D ;
SIDRANSKY, D .
NATURE GENETICS, 1995, 11 (02) :210-212
[3]  
CANMAN CE, 1994, CANCER RES, V54, P5054
[4]   INTERACTIONS BETWEEN P53 AND MDM2 IN A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY [J].
CHEN, CY ;
OLINER, JD ;
ZHAN, QM ;
FORNACE, AJ ;
VOGELSTEIN, B ;
KASTAN, MB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (07) :2684-2688
[5]   Regulation of p53 downstream genes [J].
El-Deiry, WS .
SEMINARS IN CANCER BIOLOGY, 1998, 8 (05) :345-357
[6]  
FRITSCHE M, 1993, ONCOGENE, V8, P307
[7]  
Gaidano G, 2000, GENE CHROMOSOME CANC, V27, P177, DOI 10.1002/(SICI)1098-2264(200002)27:2<177::AID-GCC9>3.0.CO
[8]  
2-O
[9]   CLINICAL IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE [J].
HARRIS, CC ;
HOLLSTEIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (18) :1318-1327
[10]  
Johns MM, 1996, CANCER RES, V56, P1151